GB201215105D0 - Method - Google Patents

Method

Info

Publication number
GB201215105D0
GB201215105D0 GB201215105A GB201215105A GB201215105D0 GB 201215105 D0 GB201215105 D0 GB 201215105D0 GB 201215105 A GB201215105 A GB 201215105A GB 201215105 A GB201215105 A GB 201215105A GB 201215105 D0 GB201215105 D0 GB 201215105D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GB201215105A
Other versions
GB2505237A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to GB201215105A priority Critical patent/GB2505237A/en
Publication of GB201215105D0 publication Critical patent/GB201215105D0/en
Priority to PCT/GB2013/052242 priority patent/WO2014030019A1/en
Publication of GB2505237A publication Critical patent/GB2505237A/en
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2510/00—Detection of programmed cell death, i.e. apoptosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GB201215105A 2012-08-24 2012-08-24 Method of screening for therapeutic agents using cell lines including a reference cell line Pending GB2505237A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB201215105A GB2505237A (en) 2012-08-24 2012-08-24 Method of screening for therapeutic agents using cell lines including a reference cell line
PCT/GB2013/052242 WO2014030019A1 (en) 2012-08-24 2013-08-27 A sreening method for identifying therapeutic agents in target cells

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201215105A GB2505237A (en) 2012-08-24 2012-08-24 Method of screening for therapeutic agents using cell lines including a reference cell line

Publications (2)

Publication Number Publication Date
GB201215105D0 true GB201215105D0 (en) 2012-10-10
GB2505237A GB2505237A (en) 2014-02-26

Family

ID=47045348

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201215105A Pending GB2505237A (en) 2012-08-24 2012-08-24 Method of screening for therapeutic agents using cell lines including a reference cell line

Country Status (2)

Country Link
GB (1) GB2505237A (en)
WO (1) WO2014030019A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0877752T3 (en) * 1996-01-23 2003-09-15 Univ Leland Stanford Junior Methods for screening transdominant effector peptides and RNA molecules
AU781478B2 (en) * 1999-08-20 2005-05-26 Johns Hopkins University School Of Medicine, The Methods and compositions for the construction and use of fusion libraries
US6582899B1 (en) * 2000-02-15 2003-06-24 Deltagen Proteomics, Inc. Methods for identifying agents that cause a lethal phenotype, and agents thereof
AU2002245648A1 (en) * 2001-03-09 2002-09-24 Todd Waldman Isogenic ss-catenin cell lines, and methods of making and using same
WO2003040168A2 (en) * 2001-11-06 2003-05-15 Enanta Pharmaceuticals, Inc. Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype
AU2003228132A1 (en) * 2002-04-19 2003-11-03 Leadd B.V. Aberrant-specific pathways
CA2546622A1 (en) * 2003-11-26 2005-06-09 Amadeo Parissenti Use of isogenic drug-resistant cell lines to determine the sequence of chemotherapeutic drug treatment
US8242057B2 (en) * 2006-06-26 2012-08-14 Cleveland Biolabs, Inc. Methods for identifying modulators of apoptosis
EP3112477A1 (en) * 2008-02-28 2017-01-04 The Ohio State University Research Foundation Microrna-based methods and compositions for the diagnosis, prognosis and treatment of prostate related disorders
EP2370566A1 (en) * 2008-12-03 2011-10-05 Università Degli Studi Di Torino Isogenic human cell lines comprising mutated cancer alleles and process using the cell lines

Also Published As

Publication number Publication date
GB2505237A (en) 2014-02-26
WO2014030019A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
GB201223172D0 (en) Method
GB201212937D0 (en) Method
GB201212932D0 (en) Method
PL2817775T3 (en) Audience-measuring method
GB201220940D0 (en) Method P
GB201213636D0 (en) Method
GB201212934D0 (en) Method
GB201210858D0 (en) Method
GB201222693D0 (en) Novel method
SG11201407032WA (en) Method
PL2809816T3 (en) Expression method
GB201218570D0 (en) Method
EP2880048A4 (en) Method
GB201208874D0 (en) Methods
GB201202198D0 (en) Method
GB201211393D0 (en) Method
GB201204280D0 (en) Methods
GB201223316D0 (en) Method
GB201222737D0 (en) Method
GB201217688D0 (en) Method
GB201214029D0 (en) method
GB201210147D0 (en) Method
GB201213858D0 (en) Method
GB201203337D0 (en) Method
GB201201332D0 (en) Method